PHARMARIVE
Board
1 director, last change in 2024BLUESTONE BV
Director (not named in the articles), permanent representative Paul RANSART
since 30-11-2019
term without a fixed end
earlier manager, until 16-01-2024
also on the board of 11 other companies
listed in the 2025 annual accounts, filed on 22-08-2026
- Signing authorityThe articles say who may bind the company, for example by signing a contract.
- “Article 13. Pouvoirs de l’organe d’administration S’il n’y a qu’un seul administrateur, la totalité des pouvoirs d’administration lui est…”deed of 16-01-2024
Permanent representatives 1
Mandates through the years
1 name, the dashed line is todayBLUESTONE
Director (not named in the articles)
Director (not named in the articles)
BoardEarliermandate already running before its first mention
Mandates as a list
- BLUESTONE
- Director (not named in the articles), from 30-11-2019 to date
- Manager, until 16-01-2024
Control
Parent
Equity €487,128
Loss €60,905 in 2025 (loss €90,665 in 2024)
Checked score 51
Source: accounts PALATINE 2024
100%
This company
PHARMARIVE
Equity €114,888
Loss €19,028 in 2025
Further up the chainBLUESTONE 51.44%
Capital
- Contribution
- €6,200
- Source
- 2025 annual accounts
Owners through the years
as the annual accounts name themOwners as a list
- PALATINE
Source: lists of holdings in the owners' accounts
Articles of association
deed of 16-01-2024 (in French)- DurationMost companies exist for an unlimited period, until they are dissolved.
- Unlimited
- Board ruleThese rules set how the board is made up, meets and takes decisions.
- At least 1 director
- Annual meetingThe shareholders approve the annual accounts, among other things, at the annual meeting.
- Third Tuesday of June at 19:00